Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R H Xu

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safetyH Y Luo, Y H Li, W Wang, et al.
ESMO Open|August 15, 2024
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trialsF Lordick, E Van Cutsem, K Shitara, et al.
ESMO Open|July 26, 2024
Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trialsF-R Liu, X-L Wei, W-N Feng, et al.
ESMO Open|May 26, 2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studiesS B Maron, R-H Xu, Z A Wainberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2026
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinomaY X Chen, Y Jin, Y K Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2017
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOST Yoshino, D Arnold, H Taniguchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2019
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F Wang, X L Wei, F H Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2026
Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized TrialF Han, Y Q Xiang, X H Wang, et al.
ESMO Open|May 26, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancerT Yoshino, A Cervantes, H Bando, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2026
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumorsD Y Ruan, S Y Lin, J J Huang, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safetyH Y Luo, Y H Li, W Wang, et al.
ESMO Open|August 15, 2024
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trialsF Lordick, E Van Cutsem, K Shitara, et al.
ESMO Open|July 26, 2024
Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trialsF-R Liu, X-L Wei, W-N Feng, et al.
ESMO Open|May 26, 2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studiesS B Maron, R-H Xu, Z A Wainberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2026
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinomaY X Chen, Y Jin, Y K Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2017
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOST Yoshino, D Arnold, H Taniguchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2019
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F Wang, X L Wei, F H Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2026
Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized TrialF Han, Y Q Xiang, X H Wang, et al.
ESMO Open|May 26, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancerT Yoshino, A Cervantes, H Bando, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2026
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumorsD Y Ruan, S Y Lin, J J Huang, et al.
Pageof 7